04/17/2026
Ending the week on a hopeful note🙏
As a community oncologist, pancreatic cancer is one of the hardest conversations we have with limited options, tough biology, and outcomes that haven’t meaningfully changed in far too long.
That’s why studies like RASolute-302 matter. More to come but exciting press release about Daraxonrasib (RMC-6236) attempts at taking a real shot at something we’ve been chasing for decades: directly targeting RAS, the engine driving most of these tumors - not just one mutation, but across variants. It has met primary and key secondary endpoints showing significant overall survival improvement in previously treated metastatic pancreatic cancer.
It’s still a phase 3 trial. It still has to prove itself..... We’ve all seen promising signals not pan out before.
But after decades of incremental progress, even the possibility of a new, mechanism-driven option feels meaningful.
Grateful for the patients, Grateful for the science pushing forward
For the first time in a while, it feels like something different with better outcome might actually be on the horizon.